Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications

Haro-Reyes, Tammy; Díaz-Peralta, Lucero; Galván‐Hernández, Arturo; Rodríguez‐López, Anahí; Rodríguez‐Fragoso, Lourdes; Ortega‐Blake, Iván

doi:10.3390/membranes12070681

Cited by 18 publications

(14 citation statements)

References 423 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytolytic SMs may also provide the producer with the ability to acquire larger variability of substrates. Next, we cannot exclude the role of some hemolytic metabolites in the streptomycete programmed cell death, as has also been reported for other cytotoxins acting on DNA [ 101 , 102 ]; though the effect of polyenes in sterol-free bacterial membranes is much less severe [ 103 ].…”

Section: Discussionmentioning

confidence: 99%

Polyenic Antibiotics and Other Antifungal Compounds Produced by Hemolytic Streptomyces Species

Bobek

Filipová

Bergman

et al. 2022

IJMS

View full text Add to dashboard Cite

Streptomyces are of great interest in the pharmaceutical industry as they produce a plethora of secondary metabolites that act as antibacterial and antifungal agents. They may thrive on their own in the soil, or associate with other organisms, such as plants or invertebrates. Some soil-derived strains exhibit hemolytic properties when cultivated on blood agar, raising the question of whether hemolysis could be a virulence factor of the bacteria. In this work we examined hemolytic compound production in 23 β-hemolytic Streptomyces isolates; of these 12 were soil-derived, 10 were arthropod-associated, and 1 was plant-associated. An additional human-associated S. sp. TR1341 served as a control. Mass spectrometry analysis suggested synthesis of polyene molecules responsible for the hemolysis: candicidins, filipins, strevertene A, tetrafungin, and tetrin A, as well as four novel polyene compounds (denoted here as polyene A, B, C, and D) in individual liquid cultures or paired co-cultures. The non-polyene antifungal compounds actiphenol and surugamide A were also identified. The findings indicate that the ability of Streptomyces to produce cytolytic compounds (here manifested by hemolysis on blood agar) is an intrinsic feature of the bacteria in the soil environment and could even serve as a virulence factor when colonizing available host organisms. Additionally, a literature review of polyenes and non-polyene hemolytic metabolites produced by Streptomyces is presented.

show abstract

Section: Discussionmentioning

confidence: 99%

Polyenic Antibiotics and Other Antifungal Compounds Produced by Hemolytic Streptomyces Species

Bobek

Filipová

Bergman

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…95 Amphotericin B is a polyene and binds to the ergosterol in the fungal cell membrane increasing the permeability and causing a disruption in the osmotic balance and eventually cell death. 104 The drug itself has a very low aqueous solubility and so is complexed with sodium deoxycholate or with lipids for intravenous use. 105 Amphotericin B has an overall efficacy of 62% reported by a meta-analysis, 100 although it has not been compared directly to echinocandins.…”

Section: Second-line Intravenous Therapymentioning

confidence: 99%

Chronic Pulmonary Aspergillosis: Clinical Presentation and Management

Evans,

Lawal,

Kosmidis

et al. 2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) refers to a number of clinical syndromes resulting from the presence and local proliferation of Aspergillus organisms in the lungs of patients with chronic lung disease. CPA is more common than was realized two decades ago. Recognition remains poor, despite recent studies from many countries highlighting the high prevalence in at-risk populations. In low- and middle-income countries, CPA may be misdiagnosed and treated as tuberculosis (TB). In addition, CPA may develop following successful TB treatment. The coronavirus disease pandemic has resulted in significant disruption to provision of TB care, likely leading to more extensive lung damage, which could increase the risk for CPA.Although CPA refers to various syndromes, the classic presentation is that of chronic cavitary pulmonary aspergillosis, which manifests as one or more progressive cavities with or without a fungal ball, accompanied by systemic and respiratory symptoms for at least 3 months. Diagnosis relies on Aspergillus immunoglobulin G in serum, as sputum culture lacks sensitivity. Differential diagnosis includes mycobacterial infection, bacterial lung abscess or necrotizing pneumonia, lung cancer, and endemic fungi.The aim of antifungal treatment in CPA is to improve symptoms and quality of life, and to halt progression, and possibly reverse radiological changes. Current recommendations suggest treatment for 6 months, although in practice many patients remain on long-term treatment. Improvement may manifest as weight gain and improvement of symptoms such as productive cough, hemoptysis, and fatigue. Surgical management should be considered in cases of diagnostic uncertainty, in significant hemoptysis, and when there is concern for lack of response to therapy. Itraconazole and voriconazole are the first-line azoles, with more experience now accumulating with posaconazole and isavuconazole. Side effects are frequent and careful monitoring including therapeutic drug monitoring is essential. Intravenous antifungals such as echinocandins and amphotericin B are used in cases of azole intolerance or resistance, which often develop on treatment. Relapse is seen after completion of antifungal therapy in around 20% of cases, mostly in bilateral, high-burden disease.Several research priorities have been identified, including characterization of immune defects and genetic variants linked to CPA, pathogenetic mechanisms of Aspergillus adaptation in the lung environment, the contribution of non-fumigatus Aspergillus species, and the role of new antifungal agents, immunotherapy, and combination therapy.

show abstract

“…The films displayed active antimicrobial functions that effectively inhibited microbial growth in fresh rice noodles, however, these additives are fossil‐based resources 30 . On the other hand, polyene compounds, such as nystatin are natural antifungal agents, which are thermally non‐stable and get partially volatilized during the melt processing with polymer composites resulting in either loss of or proportionally undesirable release of anti‐fungal activity 31 …”

Section: Introductionmentioning

confidence: 99%

Development of nystatin‐based antifungal, biodegradable polymer composite materials for food packaging via melt processing approach

Duarah,

Aleksic,

Milivojevic

et al. 2023

J of Applied Polymer Sci

View full text Add to dashboard Cite

Novel bio‐based, biodegradable packaging material was developed with multi‐functional properties of good mechanical strength, potent biocompatibility, and antifungal attributes, predominantly against fungi vital in food spoilage. Biodegradable polymer composites were prepared with a natural antifungal agent, nystatin (Nyst), by melt processing technique for the first time. Initially, Polycaprolactone (PCL) was melt‐mixed with various percentages of nystatin to produce nystatin‐encapsulated PCL composites (PCL/Nyst). The as‐prepared PCL/Nyst composites were melt‐mixed with polylactic acid (PLA) to produce nystatin PLA/PCL blend composites. Subsequently, the prepared composites were compression molded in the form of films (1 mm) for further characterization. The composite's structural properties were evaluated by SEM, FTIR, mechanical and thermal studies. In addition, the composites were tested in vitro against a panel of pathogenic fungi and for antibiofilm attributes, specifically against three Candida species (C. albicans ATCC10231, C. parapsilosis ATCC22019, and C. glabrata ATCC2001), and foodborne Penicillium sp. All the composites containing 2 to 20 wt% nystatin displayed good activity and sustained nystatin release for up to 4 days. Thus, the overall study demonstrates the potential application of natural antifungal agents in biodegradable polymers to produce novel composite films for antimicrobial packaging without inducing any toxicity, judged from the toxicity assay using nematode Caenorhabditis elegans.

show abstract

Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications

Cited by 18 publications

References 423 publications

Polyenic Antibiotics and Other Antifungal Compounds Produced by Hemolytic Streptomyces Species

Polyenic Antibiotics and Other Antifungal Compounds Produced by Hemolytic Streptomyces Species

Chronic Pulmonary Aspergillosis: Clinical Presentation and Management

Development of nystatin‐based antifungal, biodegradable polymer composite materials for food packaging via melt processing approach

Contact Info

Product

Resources

About